Steven B. Engle
Steve Engle is CEO of Averigon Consulting, an advisory firm to the life science industry. Previously, Mr. Engle was Chairman and CEO of XOMA, a developer of antibody therapeutics for inflammatory, metabolic, autoimmune, oncology, and other diseases. Prior to that, he was Chairman and CEO of La Jolla Pharmaceutical Company, which discovered the biology of B cell tolerance, developed the first B cell toleragen for lupus patients, and received an approvable letter from the FDA. Mr. Engle served as VP of Marketing for Cygnus, a drug delivery company, where he helped gain FDA approval of and launch Nicotrol for smoking cessation. He was VP of Marketing at a $50 million device company and a management consultant at Strategic Decisions Group and SRI (Stanford Research Institute) International. Mr. Engle is a board member of BayBio, former board member of BIO and former Chair of BIOCOM. Mr. Engle holds M.S.E.E. and B.S.E.E. degrees from the University of Texas with focus in biomedical engineering and was an invited operating room intern for Dr. M. E. DeBakey at Baylor Medical School.